



Presentations by Rutgers Cancer Institute of New Jersey Faculty Members at the Virtual 2020 American Society of Clinical Oncology Annual Meeting

Talks and posters are being offered on-demand starting at 8 a.m., Friday, May 29 and will be available online through the end of August. Click [here](#) for additional information.

Clinical Science Symposium

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. [Abstract #6010](#)

Author: Eugenia Girda, MD, FACOG

Oral Presentations

“Novel Targeted Therapy Approaches”

Session Type: Melanoma/Skin Cancers

Discussant: Janice M. Mehnert, MD

“Melanoma Highlights”

Session Type: Highlights of the Day

Discussant: Janice M. Mehnert, MD

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Session Type: Genitourinary Cancer

Author: Eric A. Singer, MD, MA, FACS

Poster Sessions

Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. [Abstract #8013](#)

Lead Author: Peter Cole, MD

LAG-3 overexpression in pediatric Hodgkin lymphoma. [Abstract #10531](#)

Lead Author: Scott Moerdler, MD

Senior Author: Peter Cole, MD

Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi). [Abstract #10029](#)

Senior Author: Janice Mehnert, MD

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320. [Abstract #10039](#)

Author: Janice Mehnert, MD

Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. [Abstract #7540](#)

Author: Andrew M. Evens, DO

Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites. [Abstract #8043](#)

Senior Author: Andrew M. Evens, DO

Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC). [Abstract #12068](#)

Senior Author: Andrew M. Evens, DO

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. [Abstract #9008](#)

Lead Author: Salma K. Jabbour, MD

Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial. [Abstract #9010](#)

Author: Salma K. Jabbour, MD

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC. [Abstract #9032](#)

Author: Salma K. Jabbour, MD

NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer. [Abstract #TPS9082](#)

Author: Salma K. Jabbour, MD

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. [Abstract #4020](#)

Author: Kristen Spencer, DO, MPH,

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174). [Abstract #TPS4651](#)

Author: Kristen Spencer, DO, MPH

Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. [Abstract #5041](#)

Author: Eric A. Singer, MD, MA, FACS

Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). [Abstract #4062](#)

Lead Author: Patrick M. Boland, MD

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). [Abstract #TPS4121](#)

Author: Patrick M. Boland, MD

Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study. [Abstract #4032](#)

Author: Patrick M. Boland, MD

Publication Only

Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates. [Abstract #e18040](#)

Lead Author: Eugenia Girda, MD

Authors: Alexandre Buckley de Meritens, MD, Ruth D. Stephenson, DO, FACOG, Aliza L. Leiser, MD, Mihae Song, MD

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. [Abstract #6010](#)

Author: Eugenia Girda, MD

Cyclooxygenase inhibitor use during checkpoint immunotherapy and effect on time to progression and overall survival for metastatic melanoma and non-small cell lung cancer patients. [Abstract #e22034](#)

Senior Author: Salma K. Jabbour, MD

Authors: Shang-Jui Wang, Karishma Khullar, Sinae Kim, PhD, Roman Groisberg, MD, Jyoti Malhotra, MD, Janice M. Mehnert, MD

Breast cancer receptor subtypes in East Africa: A systematic review and meta-analysis. [Abstract #e19074](#)

Authors: Coral Omene, MD, Shridar Ganesan, MD, PhD

Trends in the use of administrative databases in urologic oncology: 2000-2019. [Abstract #e17111](#)

Author: Eric A. Singer, MD, MA, FACS

Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. [Abstract #e17058](#)

Senior Author: Thomas L. Jang, MD, MPH, FACS

Authors: Sinae Kim, PhD, Isaac Kim, MD, PhD, Eric A. Singer, MD, MA, FACS